DDI-DrugBank.d720.s0 >> Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. >> 0-4
DDI-DrugBank.d720.s1 >> Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided. >> 80-89,105-126,134-150,155-166,173-183
DDI-DrugBank.d720.s2 >> MAO-A inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure. >> 0-15,24-34
DDI-DrugBank.d720.s3 >> Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan. >> 22-42,74-89,112-150,153-157,167-176,179-189,192-201,204-213,322-332
DDI-DrugBank.d720.s4 >> If concomitant treatment with sumatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised. >> 30-40,49-52
